Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹278 Cr
verified against source
Revenue YoY
14%
reported change
EBITDA
₹99 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Concord Biotech reported Q3 FY26 revenue of ₹278 crore, up 14% YoY, driven by API growth of 24% to ₹219 crore. EBITDA was ₹99 crore (margin 35.6%), impacted by injectable startup costs and Stellon subsidiary expenses; excluding these, margin was 40%. PAT declined to ₹64 crore due to a one-time labor code provision of ₹3 crore and lower other income. Management noted that H1 headwinds (US tariff uncertainty, delayed EU certification, Middle East tender deferrals) are easing, with order momentum recovering. The injectable facility received WHO GMP certification, targeting domestic and emerging markets with a peak revenue potential of ₹600 crore. FY26 is expected to remain below historical averages, but FY27 should normalize to historical growth rates of ~18%. Key risks include delayed ramp-up of injectables and persistent geopolitical tensions in the Middle East.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects FY27 performance to normalize to historical growth rates of around 18%, driven by recovery in core API and injectable ramp-up.
- The injectable facility, now WHO GMP certified, has a peak revenue potential of approximately ₹600 crore, with initial focus on domestic market.
- Annual capex is expected to be in the range of ₹100-150 crore, including maintenance and growth projects.
Risks flagged
- Tender-based supplies to the Middle East remain on hold due to geopolitical tensions, with no clear timeline for resumption.
- The injectable facility is still in early stages; revenue contribution was insignificant in Q3, and scaling up may take longer than anticipated.
- While tariffs do not apply to already-launched generics, new product launches could be impacted if tariff policies change, as noted in analyst Q&A.
Key quotes
- We have started with Stellon Biotech, our US subsidiary, to drive marketing, distribution and commercialization of our products in the US, creating a direct commercial footprint.
- Excluding injectables related startup cost and cost associated with our US subsidiary, EBITDA margins remain in the range of 40% for Q3 and 9M FY26.
- While FY26 is expected to remain below our historical averages, we anticipate that FY27 and beyond will reflect a normalization in performance.
Research modules